58,688 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 58,688 shares of the company’s stock, valued at approximately $1,125,000.

A number of other large investors have also bought and sold shares of VRDN. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Viridian Therapeutics by 17.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock worth $318,000 after acquiring an additional 2,036 shares during the last quarter. AlphaCentric Advisors LLC raised its stake in Viridian Therapeutics by 20.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company’s stock worth $341,000 after buying an additional 2,500 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Viridian Therapeutics during the 3rd quarter valued at about $149,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Viridian Therapeutics by 30.7% in the second quarter. The Manufacturers Life Insurance Company now owns 31,687 shares of the company’s stock valued at $412,000 after buying an additional 7,450 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Viridian Therapeutics in the 3rd quarter valued at $208,000.

Wall Street Analyst Weigh In

Several analysts have issued reports on VRDN shares. Wells Fargo & Company reissued an “equal weight” rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. TD Cowen began coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They issued a “buy” rating on the stock. Finally, Royal Bank of Canada increased their target price on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $35.70.

Viridian Therapeutics Stock Up 1.1 %

VRDN stock opened at $19.43 on Thursday. The business’s 50 day simple moving average is $19.42 and its 200 day simple moving average is $19.40. Viridian Therapeutics, Inc. has a 1-year low of $11.40 and a 1-year high of $27.20. The firm has a market capitalization of $1.54 billion, a PE ratio of -4.51 and a beta of 1.13. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. As a group, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.